CER Daily Newsfeed

Video: From Data to Dialogue: Transforming Oncology With Real-World Evidence

(11/29, Skylar Jeremias, The American Journal of Managed Care) “Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.” View Video

Gene Therapy Explosion Forces Employer Coverage to Get Creative

(12/2, Lauren Clason, Bloomberg Law) reports “...Several manufacturers offer pricing flexibility through rebates tied to the therapy’s results or a series of payments that can be made over time. These deals are typically struck with insurance companies or pharmacy benefit managers that offer employers supplemental coverage. The arrangements help when there’s ‘true uncertainty’ about a drug, but often function as just another rebate off the list price, said Anna Kaltenboeck, who leads ATI Advisory’s Prescription Drug Reimbursement Practice. Critics allege the current rebate system incentivizes higher list prices instead of driving them down.” Full

Big Pharma Pushes Trump Team to Ease Medicare Drug Price Negotiation Rules

(11/27, Michael Erman, Patrick Wingrove, Maggie Fick, Reuters) reports “...One source at a big pharmaceutical company said the company had both phone calls and in-person meetings with members of the Trump transition team to discuss possible changes to the IRA. The company hopes a Republican Congress and the Trump administration would remove the distinction in how the easier to produce drugs are treated. ‘They have been receptive,’ the source said, declining to say whom the company had spoken to on the transition team.” Full